In line with this assumption, we recently reported that tamoxifen-resistant BCCs do express lower levels of FoxO3a compared to parental cell lines and that its re-expression is able to restore the sensitivity to the antiestrogen and to strongly reduce tumor mass in tamoxifen-resistant mouse models [9]. This evidence concerns the gene FOXO3 and neoplasm.